There is more movement in the active pharmaceutical ingredient manufacturing market, this time in France, where peptide specialist Synprosis was snapped up by fine chemical maker Provence Technologies Group.
Fresh off its latest R&D partnership, Dutch antibody specialist arGEN-X is planning to go public in Brussels, looking to raise cash and advance its proprietary pipeline.
Molecular diagnostic company CareDx hopes a new name, a new deal and an IPO for up to $50 million will give it new life. The company has marketed blood-based test AlloMap to monitor heart transplant patients since 2005 but has yet to breakeven.
In this week's EuroBiotech Report, British biotechs already buoyed by the arrival of funds backed by AstraZeneca and Eli Lilly got more reasons to be cheerful when Imperial Innovations outlined plans to raise £150 million ($251 million). And if Neil Woodford gets his way, another early stage-focused fund will be setting up in England. And more.
The European Medicines Agency has agreed to an accelerated review of Boehringer Ingelheim's much-watched lung disease therapy, likely shortening its path to market.
AbbVie is expecting to get its highly-anticipated all-oral hepatitis C drug approved soon and has geared up its manufacturing capacity to be ready. An expansion in Ireland adds to a string of projects the drugmaker has announced as the spinoff from Abbott Laboratories adds to its global manufacturing network.
As Europe prepares to open its clinical trial data vaults in a move toward greater transparency, the British Medical Journal is criticizing the European Medicines Agency for seemingly backtracking on its promises to make important information available to consumers.
In this week's EuroBiotech Report, Bayer became the most recent biopharma to tap Dutch biotech arGEN-X for its llama-based antibody discovery platform; Eli Lilly made its first-ever investment in a British venture fund; and British biotech Oxford BioMedica hopes to raise £25.7 million to finance its gene therapy pipeline. And more.
Eli Lilly has taken the unusual step of investing in Epidarex Capital's new, $80 million life sciences fund, with an eye to backing the Scotland-based group's portfolio of academic spinouts. This was Lilly's first investment in a U.K. venture fund.
Teva's $4-billion-a-year multiple sclerosis treatment Copaxone is slated to lose patent protection next year, and the Israeli drugmaker is struggling to move the needle on its planned replacement, enduring another rejection from European reviewers.